Biocon CEO Siddharth Mittal outlines the company’s strategy in the competitive GLP-1 market. Focusing on liraglutide’s launch in the US and Europe, he highlights opportunities in emerging markets. While semaglutide is a longer-term play, Biocon is actively filing for approvals, anticipating launches in 2027.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets